Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age.
The main objective of this study was to assess in 5-6-year-old French children (n=162) the persistence of antibodies induced by a primary series vaccination (at 2-4 months of age) with a pentavalent whole-cell pertussis combined vaccine (DTwcP-IPV-Hib; Pentacoq) and a first booster (at 12-16 months of age) with a pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac). The second objective was to evaluate in these 5-6-year-old French children the safety and the immunogenicity of a tetravalent pertussis combined vaccine (DTacP-IPV, Tetravac) given as a second booster.


RESULTS
before the 2nd booster, more than 90% of children had antibody titers above the defined threshold for polyribosyl ribitol phosphate (PRP), tetanus, diphtheria and poliomyelitis; antibody titers were very low for pertussis. One month after the second booster, all children had sero-protective post-booster titers for tetanus, diphtheria and poliomyelitis types 1-3; over 90% of children had a four-fold rise in titers against DTacP-IPV antigens. Adverse events were mostly solicited reactions, with no serious adverse event. A strong anamnestic response was also observed after the second booster injection with Tetravac, with a satisfactory safety profile.


CONCLUSIONS
Pentavac and Tetravac (acellular pertussis containing vaccines) may thus be administered as first and second boosters respectively, in children primed with Pentacoq (whole-cell pertussis containing vaccine).
Langue
Jacques
J
L'Espace Médical, Saint-Prest en Jarez, France.
Matisse
Noëlle
N
Pacoret
Patrick
P
Undreiner
François
F
Boisnard
Florence
F
Soubeyrand
Benoît
B
D000907:Antibodies, Bacterial / Q000032:analysis* / Q000096:biosynthesis; D000917:Antibody Formation / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000009:adverse effects / Q000276:immunology; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007117:Immunization, Secondary; D007124:Immunoenzyme Techniques; D007156:Immunologic Memory; D007223:Infant; D008297:Male; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology*; D023321:Poliovirus Vaccines / Q000009:adverse effects / Q000276:immunology; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology
D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D010567:Pertussis Vaccine; D023321:Poliovirus Vaccines; D017778:Vaccines, Combined